Since induced pluripotent stem cells (iPSCs) were first produced in 2006 from mouse cells and in 2007 from human cells, research scientists have recognized the wide-ranging potential of the cell type, including the possibility of using them in drug and toxicology screening, disease modeling, and cellular therapy applications ranging from gene correction, to whole tissue regeneration, individualized medicine, and more.
Since the discovery of iPSCs, the commercial sector has also recognized the huge profits that could potentially be generated from the cell type, and the question being explored among the private sector has been how to generate maximal commercial value through the development of iPSC applications and technologies.
Awards Given to iPSC Researchers
No matter how the value of iPSCs is assessed, it is clear that induced pluripotent stem cells have incredible potential. This is confirmed by the number of awards that have been given to early pioneers in this area of research, including those shown in the table below.
Each of these individuals has been recognized for their exceptional contributions to the field of iPSC research. They are renowned industry experts, innovative thought leaders, and of course, highly-sought after speakers, advisors, and board members.
Their individual opinions on iPSC topics can substantially alter public perception and their accomplishments have driven forward an entire commercial industry for iPSC products, therapies, and technologies.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.